Gland Pharma Ltd
Healthcare | Mid Cap
Gland Pharma Ltd. presents a picture of exceptional financial strength, marked by outstanding profitability and impressive growth. The company is extremely stable, operating with almost no debt, which makes it highly resilient to financial shocks. It is rapidly expanding its sales, profits, and assets, indicating a successful business strategy and strong market demand. Shareholders benefit from high earnings, a strong asset backing per share, and attractive dividends. However, there is a significant contrast in its operational efficiency. The company struggles to use its assets effectively to generate sales and is slow in selling inventory and collecting payments. This inefficiency is a notable weakness in an otherwise stellar financial profile. Looking ahead, while growth and profitability are expected to remain strong, the key challenge for the company will be translating its significant investments into more productive and efficient operations.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsOvervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio8.40
- Profitability Ratio10.00
- Efficiency Ratio2.33
- Coverage Ratio8.40
- Solvency Ratio10.00
- Liquidity Ratio9.20
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekBullish
- 1 MonthBullish
Gland Pharma Ltd. presents a picture of exceptional financial strength, marked by outstanding profitability and impressive growth. The company is extremely stable, operating with almost no debt, which makes it highly resilient to financial shocks. It is rapidly expanding its sales, profits, and assets, indicating a successful business strategy and strong market demand. Shareholders benefit from high earnings, a strong asset backing per share, and attractive dividends. However, there is a significant contrast in its operational efficiency. The company struggles to use its assets effectively to generate sales and is slow in selling inventory and collecting payments. This inefficiency is a notable weakness in an otherwise stellar financial profile. Looking ahead, while growth and profitability are expected to remain strong, the key challenge for the company will be translating its significant investments into more productive and efficient operations.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
27.88
Industry Median
28.62
Mid Cap Median
36.34
P/E RATIO
35.27
P/B RATIO
3.50
Industry Median
3.17
Mid Cap Median
7.64
P/S RATIO
5.64
Industry Median
3.42
Mid Cap Median
6.30
Others
PEG RATIO
37.92
EV/EBITDA RATIO
17.19
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹2199 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Concall Report⬤3rd Feb 26
Q3 FY26 Earnings Conference Call
BULLISH SENTIMENT
The company is in a phase of exceptional growth. It is expanding its revenue, profits, and asset base at an outstanding rate. This rapid expansion across all key growth indicators points to strong market positioning, high demand for its products or services, and a successful strategy for scaling the business. This robust growth is a major strength and a key driver of value for the company.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 27.09 | -17.63 | 56.28 | -0.86 | 14.51 |
| Operating Profit Growth Rate | 15.98 | -32.12 | 30.05 | -4.8 | 28.45 |
| Earnings Per Share (EPS) Growth | 21.02 | -35.7 | -1.1 | -9.59 | 47.05 |
| Asset Growth Rate | 20.6 | 12.05 | 20.88 | 5.3 | 11.98 |
| Net Income Growth Rate | 21.56 | -35.56 | -1.15 | -9.46 | 46.92 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial metrics reflect a very strong position for shareholders. Key indicators such as earnings per share (both adjusted and cash-based) and book value are excellent, demonstrating high profitability and intrinsic value. The company also offers a strong dividend. The only note of caution is the very high level of capital spending, which, while intended for growth, represents a significant use of cash.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 75.56 | 51.31 | 48.25 | 43.62 | 65.25 |
| Cash Earnings Per Share (Cash EPS) | 82.62 | 58 | 69.81 | 67.31 | 90.69 |
| Book Value Per Share | 447.31 | 497.38 | 545.19 | 571.88 | 647.31 |
| Dividend Per Share (DPS) | 0 | 0 | 20.17 | 17.81 | 19.95 |
| Capital Expenditures (CapEx) | 522 | 223 | 397 | 394 | 493 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability is excellent. It demonstrates a superior ability to convert revenue into profit at every level, from gross margin to net margin. It also generates outstanding returns on the capital, equity, and assets it employs. This all-around strength in profitability indicates highly effective management, strong pricing power, and efficient cost control, making it a key highlight of the company's financial health.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 31.81 | 24.22 | 17.44 | 15.87 | 18.75 |
| Return on Capital Employed (ROCE) | 25 | 15 | 14 | 12 | 15 |
| Return on Equity (ROE) | 16.93 | 9.81 | 8.85 | 7.64 | 9.92 |
| Return on Assets (ROA) | 19.27 | 11.68 | 12.56 | 11.36 | 13.03 |
| Operating Margin | 34.31 | 28.28 | 23.53 | 22.6 | 25.35 |
| Net Margin | 27.54 | 21.54 | 13.63 | 12.45 | 15.97 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's operational efficiency is a significant area of concern. Across the board, key metrics show that the company struggles to use its assets—including fixed assets, inventory, and capital—to generate sales effectively. It also takes a long time to sell its products and collect payments from customers. This inefficiency represents a drag on performance and indicates a disconnect between the company's investments in assets and its revenue-generating capabilities.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 2.93 | 2.31 | 1.44 | 1.35 | 1.43 |
| Inventory Turnover Ratio | 2.44 | 1.75 | 2.6 | 2.83 | 3.05 |
| Receivables Turnover Ratio | 5.04 | 3.73 | 4.66 | 3.65 | 3.77 |
| Days Sales in Inventory Ratio | 149.59 | 208.57 | 140.38 | 128.98 | 119.67 |
| Receivable Days | 72.42 | 97.86 | 78.33 | 100 | 96.82 |
| Capital Turnover Ratio | 0.61 | 0.46 | 0.64 | 0.61 | 0.61 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's ability to cover its financial obligations is very strong. With earnings far exceeding its interest payments, there is virtually no risk of default on its debt. Furthermore, its profits provide a safe and sustainable cover for dividend payments to shareholders. This indicates a high degree of financial security and a reliable capacity to service both its debt and equity commitments.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 324.8 | 151.71 | 44.58 | 26.31 | 45.39 |
| Equity Dividend Coverage Ratio | 2.33 | 2.38 | 3.12 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency is outstanding, representing a position of maximum financial stability. The business operates with virtually no debt, financing its operations and growth almost entirely through equity. This extremely conservative financial structure means there is negligible risk of financial distress due to borrowing. This indicates a robust, self-reliant balance sheet that is highly resilient to economic downturns.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0 | 0 | 0.02 | 0.01 | 0.01 |
| Debt to Equity Ratio | 0 | 0 | 0.02 | 0.01 | 0.01 |
| Equity Ratio | 1 | 1 | 0.98 | 0.99 | 0.99 |
| Debt To Asset Ratio | 0 | 0 | 0.01 | 0.01 | 0.01 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is exceptionally strong. It possesses a very high capacity to meet its short-term financial obligations using its available assets. This is primarily driven by its substantial holdings of cash and other highly liquid assets. While cash generation from operations is average, the overall liquidity cushion is more than sufficient, indicating very low risk of short-term financial distress and providing significant operational flexibility.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 8.92 | 8.63 | 3.72 | 3.62 | 3.76 |
| Quick Ratio | 7.15 | 6.24 | 2.76 | 2.73 | 2.9 |
| Cash Ratio | 4.61 | 4.63 | 1.06 | 1.35 | 1.64 |
| Operating Cash Flow Ratio | 1.18 | 0.45 | 0.58 | 0.48 | 0.5 |
Current Ratios
Quick Ratios
Cash Ratios
Operating Cash Flow Ratios
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 38.14 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 2 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 49.64 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 3 | Gland Pharma Ltd | 7.91 | 35.27 | Overvalued | 1630.00 | 78.88 | 1027.00 |
| 4 | Neuland Laboratories Ltd | 7.84 | 61.14 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 5 | Granules India Ltd | 7.73 | 32.77 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 6 | Ajanta Pharma Ltd | 7.72 | 36.27 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 7 | Alembic Pharmaceuticals Ltd | 7.54 | 22.23 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 8 | Syngene International Ltd | 7.44 | 56.08 | Overvalued | 918.00 | 7.55 | 317.00 |
| 9 | Emcure Pharmaceuticals Ltd | 7.40 | 36.42 | Neutral | 1865.00 | 38.66 | 941.00 |
| 10 | ERIS Lifesciences Ltd | 7.15 | 32.39 | Neutral | 1120.00 | 17.61 | 648.00 |
| 11 | Ipca Laboratories Ltd | 6.33 | 35.26 | Neutral | 1979.00 | 44.64 | 1184.00 |
| 12 | Piramal Pharma Ltd | 5.83 | -64.86 | Neutral | 922.00 | 5.27 | -326.00 |
| 13 | Jubilant Pharmova Ltd | 5.71 | 38.62 | Neutral | 1260.00 | 1.25 | 398.00 |
| 14 | Natco Pharma Ltd | 5.69 | 11.22 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 15 | Wockhardt Ltd | 5.07 | 153.40 | Neutral | 652.00 | 19.51 | 199.00 |
| 16 | Pfizer Ltd | 3.45 | 45.16 | Neutral | -82.00 | 157.92 | 300.00 |
Management effectiveness for Gland Pharma presents a mixed picture. On the positive side, management demonstrates excellent financial prudence with negligible debt, a very strong interest coverage ratio, and the recent initiation of dividend payments. They also achieved a remarkable sales rebound in FY24. However, these strengths are overshadowed by significant operational weaknesses. There is a severe and persistent decline in profitability margins (OPM, NPM) and capital efficiency metrics (ROCE, ROE) over multiple years. The inability to translate strong sales growth into profit growth in FY24 is a major concern, pointing to challenges in cost control and operational efficiency.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Strong Promoter Holding | 57.86% | Strong |
| Low Debt/Equity Ratio | 0.04 | Excellent | |
| Strong Sales Growth (FY24) | 56.29% | Very Strong | |
| Increasing DII Holding | 25.23% | Improving | |
| CONS | Declining Profitability (OPM) | 24% (from 38%) | Declining |
| Weak Capital Efficiency (ROCE) | 14% (from 28%) | Declining | |
| High Cash Conversion Cycle | 250 Days | Weak | |
| Disconnect in Sales vs. Profit | -6% Profit Growth | Inconsistent |
Financial Performance & Growth
The company's financial performance is characterized by high volatility and declining profitability. While sales growth rebounded impressively in FY24 to 56.3% after a 17.6% decline in FY23, this growth did not translate to the bottom line, as net profit fell by 6%. This indicates significant margin pressure. A multi-year analysis reveals a consistent and concerning downward trend in profitability. Operating Profit Margin (OPM) has eroded from a healthy 38% in FY21 to 24% in FY24. This deterioration in operational efficiency is a key weakness, as the management has been unable to protect margins despite revenue expansion. The inconsistency between top-line growth and bottom-line results points to underlying issues in cost structure or pricing power.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Sales Growth (%) | 31.5% | 27.1% | -17.6% | 56.3% |
| Profit Growth (%) | 31% | 21% | -32% | -6% |
| OPM (%) | 38% | 34% | 28% | 24% |
Capital Efficiency & Returns
Management's effectiveness in utilizing capital has shown a poor and declining trend. Key metrics for capital efficiency have deteriorated significantly over the past few years. Return on Capital Employed (ROCE) has been halved, falling from 28% in FY21 to just 14% in FY24. Similarly, Return on Equity has also seen a substantial decline, with the 3-year compounded average at 9%. This indicates that the company is generating progressively lower returns on the capital invested in the business. Furthermore, working capital management appears inefficient, as reflected by a high and volatile Cash Conversion Cycle (CCC), which stood at 250 days in FY24 after peaking at an alarming 382 days in FY23. This ties up significant cash in operations.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| ROCE (%) | 28% | 25% | 15% | 14% |
| Return on Equity (3-Yr Avg) | 9% | |||
| Cash Conversion Cycle (Days) | 285 | 214 | 382 | 250 |
Financial Health & Prudence
The company exhibits an excellent state of financial health, managed with great prudence. The balance sheet is exceptionally strong with a negligible level of debt. Even with an increase in borrowings in the latest year, the Debt-to-Equity ratio stood at a very low 0.04 in March 2024. This conservative approach to leverage minimizes financial risk. Consequently, the company's ability to service its interest obligations is outstanding, with the Interest Coverage Ratio at a robust 44.5x in FY24. A further positive signal is the management's decision to initiate a dividend payout, with a healthy payout ratio of 43% in FY24. This demonstrates a commitment to sharing profits directly with shareholders, backed by a strong and stable financial position.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Borrowings (Cr) | 4 | 5 | 4 | 372 |
| Debt/Equity Ratio | 0.00 | 0.00 | 0.00 | 0.04 |
| Interest Coverage Ratio | 446x | 325x | 152x | 44.5x |
| Dividend Payout % | 0% | 0% | 0% | 43% |
Shareholding & Ownership Structure
The ownership structure is a source of strength, reflecting strong insider and growing domestic institutional confidence. The promoter holding remains high and stable at 57.86%, indicating a strong alignment of interests between the management and shareholders. While the stake of Foreign Institutional Investors (FIIs) has seen a notable decline over the past three years, falling from 11.87% to 3.59%, this has been more than offset by a significant vote of confidence from Domestic Institutional Investors (DIIs). The DII holding has more than doubled from 11.25% in March 2021 to 25.23% in March 2024. This strong buying from DIIs suggests a positive perception of the company's long-term prospects within the domestic market.
| Shareholder (%) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Promoters | 58.25% | 58.00% | 57.86% | 57.86% |
| FIIs | 11.87% | 10.72% | 4.33% | 3.59% |
| DIIs | 11.25% | 12.46% | 23.23% | 25.23% |
The overall risk profile reflects a significant disparity between operational risk and financial risk. The primary concern is operational, stemming from deteriorating profitability and efficiency. The inability to convert a 56% sales growth into profit growth in FY24 is a major red flag, highlighting severe cost pressures. This trend of declining margins and returns (ROCE, ROE) constitutes a material risk to future value creation. However, this high operational risk is partially mitigated by an extremely low financial risk profile. The company is virtually debt-free, which provides a substantial buffer and financial flexibility to navigate operational challenges.
Operational Cost Control
A significant red flag arises from the sharp divergence between revenue and profit growth in FY2024. While sales surged by 56.3%, net profit contracted by 6%. This disconnect is not an anomaly but the result of substantial increases in operating expenditures. The data shows that Employee Cost as a percentage of sales nearly doubled from 11.1% to 22.2% in a single year, and depreciation expenses also more than doubled. These cost escalations, likely linked to acquisitions and capital expenditure, have erased the benefits of top-line growth and severely impacted profitability. This situation points to significant cost control challenges and integration risks following a period of expansion.
| Metric | Mar 2023 | Mar 2024 | Change |
|---|---|---|---|
| Sales Growth (%) | -17.6% | 56.3% | - |
| Net Profit Growth (%) | -32.0% | -6.0% | - |
| Employee Cost % of Sales | 11.13% | 22.19% | +11.06 p.p. |
| Depreciation (Cr) | 147 | 345 | +135% |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102199.75Bearish
- SMA 202206.05Bearish
- SMA 502233.19Bearish
- EMA 102200.80Bearish
- EMA 202205.34Bearish
- EMA 502223.62Bearish
- DEMA 102197.01Bullish
- DEMA 202194.80Bullish
- DEMA 502199.77Bearish
- TEMA 102196.30Bullish
- TEMA 202198.76Bearish
- TEMA 502182.21Bullish
- MACD-7.37Bullish
- ADX17.73Weak Trend
- IndicatorValueSignal
- RSI44.55Neutral
- CCI-44.38Neutral
- ROC 9-1.29Bearish
- ROC 14-0.10Bearish
- ROC 25-0.18Bearish
- Stoch K17.31Oversold
- Stoch D16.49Oversold
- IndicatorValueSignal
- BB Upper2238.06Neutral
- BB Middle2206.05Neutral
- BB Lower2174.05Neutral
- ATR20.32Low Volatility
- IndicatorValueSignal
- MFI44.43Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102204.32Bearish
- SMA 202201.43Bearish
- SMA 502243.82Bearish
- EMA 102201.85Bearish
- EMA 202212.00Bearish
- EMA 502227.34Bearish
- DEMA 102195.17Bullish
- DEMA 202191.13Bullish
- DEMA 502236.68Bearish
- TEMA 102198.88Bearish
- TEMA 202188.82Bullish
- TEMA 502184.78Bullish
- MACD-14.68Bullish
- ADX23.18Weak Trend
- IndicatorValueSignal
- RSI43.36Neutral
- CCI-32.55Neutral
- ROC 9-0.10Bearish
- ROC 140.38Bullish
- ROC 25-4.72Bearish
- Stoch K30.13Neutral
- Stoch D27.89Neutral
- IndicatorValueSignal
- BB Upper2230.99Neutral
- BB Middle2201.42Neutral
- BB Lower2171.86Neutral
- ATR30.16Low Volatility
- IndicatorValueSignal
- MFI58.92Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102201.44Bearish
- SMA 202245.27Bearish
- SMA 502244.30Bearish
- EMA 102212.50Bearish
- EMA 202227.58Bearish
- EMA 502183.49Bullish
- DEMA 102192.40Bullish
- DEMA 202216.95Bearish
- DEMA 502311.81Bearish
- TEMA 102190.23Bullish
- TEMA 202180.39Bullish
- TEMA 50N/AN/A
- MACD-10.65Bearish
- ADX27.43Strong Trend
- IndicatorValueSignal
- RSI45.18Neutral
- CCI-79.11Neutral
- ROC 9-1.10Bearish
- ROC 14-3.19Bearish
- ROC 25-1.36Bearish
- Stoch K13.54Oversold
- Stoch D16.65Oversold
- IndicatorValueSignal
- BB Upper2349.03Neutral
- BB Middle2245.27Neutral
- BB Lower2141.51Neutral
- ATR53.00Low Volatility
- IndicatorValueSignal
- MFI47.20Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102243.74Bearish
- SMA 202266.41Bearish
- SMA 502007.84Bullish
- SMA 1001880.82Bullish
- SMA 2001858.09Bullish
- EMA 102227.14Bearish
- EMA 202202.75Bearish
- EMA 502065.40Bullish
- EMA 1001951.68Bullish
- EMA 2001874.04Bullish
- DEMA 102220.65Bearish
- DEMA 202287.55Bearish
- DEMA 502243.19Bearish
- DEMA 1002087.46Bullish
- DEMA 2001965.55Bullish
- TEMA 102186.16Bullish
- TEMA 202249.91Bearish
- TEMA 502333.23Bearish
- TEMA 1002197.24Bullish
- TEMA 2002034.78Bullish
- MACD53.39Bearish
- ADX32.00Strong Trend
- IndicatorValueSignal
- RSI53.60Neutral
- CCI-102.63Oversold
- ROC 14-2.12Bearish
- ROC 2519.41Bullish
- Stoch K10.99Oversold
- Stoch D12.35Oversold
- IndicatorValueSignal
- BB Upper2359.68Neutral
- BB Middle2266.42Neutral
- BB Lower2173.15Neutral
- ATR88.87Low Volatility
- IndicatorValueSignal
- MFI59.11Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 201867.05Bullish
- SMA 501863.74Bullish
- EMA 201937.67Bullish
- EMA 501844.80Bullish
- DEMA 202067.54Bullish
- DEMA 501918.61Bullish
- TEMA 202174.87Bullish
- TEMA 501980.30Bullish
- MACD115.37Bullish
- ADX29.99Strong Trend
- IndicatorValueSignal
- RSI64.72Neutral
- CCI221.34Overbought
- ROC 1435.54Bullish
- ROC 2535.32Bullish
- Stoch K83.67Overbought
- Stoch D85.45Overbought
- IndicatorValueSignal
- BB Upper2306.22Neutral
- BB Middle1867.05Neutral
- BB Lower1427.87Neutral
- ATR153.50High Volatility
- IndicatorValueSignal
- MFI85.20Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 61847.95Bullish
- SMA 121878.14Bullish
- SMA 241790.23Bullish
- EMA 61910.61Bullish
- EMA 121853.04Bullish
- EMA 241832.39Bullish
- DEMA 61992.55Bullish
- DEMA 121918.57Bullish
- DEMA 241788.32Bullish
- TEMA 62050.03Bullish
- TEMA 121965.79Bullish
- TEMA 24N/AN/A
- MACD-237.12Bullish
- ADX11.70Weak Trend
- IndicatorValueSignal
- RSI53.93Neutral
- CCI77.93Neutral
- ROC 2531.49Bullish
- ROC 50-31.25Bearish
- Stoch K56.77Neutral
- Stoch D56.36Neutral
- IndicatorValueSignal
- BB Upper2154.68Overbought
- BB Middle1768.24Neutral
- BB Lower1381.79Neutral
- ATR294.64High Volatility
- IndicatorValueSignal
- MFI70.72Neutral